Evaluación angiográfica de la respuesta a la quimioterapia neoadyuvante en osteosarcoma

Osteosarcoma is the most frequent oseous tumor in childhood. 30 years ago, all patients were submitted to amputation. Recently, the use of neoadyuvant chemotherapy had changed the prognosis for patients with this tumor; giving them the opportunity to save the limb and life. The use of intraarterial (IA) chemotherapy is even better than the intravenous (IV) route. The purpose of this report is to present our experience wiht IA chemotherapy and the evaluation of the response with arteriography. 1. Young J, Miler R. Incidence of malignant tumors in US children. J Pediatr 1975; 86: 254. 2. Bramwell VHC. The role of chemotherapy in the management of non-metastatic operable extremity osteosarcoma. Sem in Oncology 1997; 5: 561-571. 3. Jaffe N. Chemotherapy for malignant bone tumors. Orthop Clin of North Am 1989; 3: 487-503. 4. Jaffe N, Smith D, Jaffe MR, et al. Intra-arterial cisplatin in the management of stage IIB osteosarcoma in the pediatric and adolescent age group. Clin Orthop 1991; 270: 15-21. 5. Raymond KA, Simms W, Ayala AG. Osteosarcoma: specimen management following primary chemotherapy. Hem/Oncol Clin of North Am 1995; 4:841-868. 6. Winkler K, Beron G, Kotz R, et al. Neoadjuvant chemotherapy for osteogenic sarcoma: results of a cooperative German/Austrian study. J Clin Oncol 1984; 2: 617-624. 7. Jaffe N, Jaffe D, Raymond K, et al. Pediatric osteosarcoma: treatment of the primary tumor with intravenous cis-Diamminedichloroplatinum II (CDP): comparison of the results with the reported efficacy of intra-arterial CDP. Int J Oncol 1993; 3: 273-278. 8. Bacci G, Picci C, Ruggieri P, et al. Primary chemotherapy and delayed surgery (neoadjuvant chemotherapy) for osteosarcoma of the extremities. Cancer 1990; 65: 2539-2553. 9. Jaffe N, Knapp J, Chuang UP, et al. Osteosarcoma: intra-arterial treatment of the primary tumor with cis-Diamminechloroplatinum II(CDP): Angiographic, pathologic and pharmacologic studies. Cancer 1983; 51: 402-407. 10. Marshall JL, Andrews PA. Preclinical and clinical experience with Cisplatin resistance. Hem/Oncology Clin of North Am 1995; 2: 415-429. 11. Los G, Muggia FM. Platinum resistance: experimental and clinical status. Hem/Oncol Clin of North Am 1994; 2: 411-429. 12. Rosen G. Pre-operative (neoadjuvant) chemotherapy for osteogenic sarcoma: A ten-year experience. Orthopaedics 1985; 8: 659-664. 13. Souhami RL, Craft AW, Van der Eijken JW, et al. Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. The Lancet 1997; 350: 911-917. 14. Goldsby RE, Pappin AL, Pysher TJ, et al. Impact of neoadjuvant ifosfamide-based regimens on the clinical and histologic response of childhood osteosarcoma. Int Jour Ped Hem/Oncol 1990; 4: 143-149. 15. Provisor EJ, Ettinger LJ, Nachman JB, et al. Treatment of nonmetastatic osteosarcoma of the extremity with preoperative and postoperative chemotherapy: a report from the Children’s Cancer Group. J Clin Oncol 1997; 15: 76-84. 16. Meyers PA, Jeller G, Healey J, et al. Chemotherapy for nonmetastatic osteosarcoma: the Memorial Sloan Kettering experience. J Clin Oncol 1992; 10: 5-15. 17. Carrasco CH, Charnsangavej C, Raymond KA, et al. Osteosarcoma angiographic assessment of response to preoperative chemotherapy. Radiology 1989; 170: 839-842. Referencias